Brainstorm cell therapeutics to present new biomarker data suggesting als patients may benefit from longer-term treatment with nurown

The data will be presented at the annual als drug development summit, which is focused on identifying transformative als targets, seeking translational biomarkers and propelling more clinical approvals new york , may 20, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that als patients may benefit from longer-term treatment with debamestrocel (nurown®). the company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers dedicated to als research at the 3rd annual als drug development summit, to take place may 21 to 23, 2024 in boston ma.
BCLI Ratings Summary
BCLI Quant Ranking